Transcriptional regulation of the human ALDH1A1 promoter by the oncogenic homeoprotein TLX1/HOX11 by Rice, K.L. et al.
[page 70] [Hematology Reviews 2009; 1:e13]
Transcriptional regulation of
the human ALDH1A1 promoter
by the oncogenic homeoprotein
TLX1/HOX11 
Kim L. Rice,
1 Mansour Heidari,
1
Ross H. Taplin,
2 Ursula R. Kees,
3
Wayne K. Greene
1
1School of Veterinary and Biomedical
Sciences, Faculty of Health Sciences,
Murdoch University, Australia; 
2School of Chemical and Mathematical
Sciences, Faculty of Minerals and Energy,
Murdoch University, Australia;
3Division of Children’s Leukaemia and
Cancer Research, Telethon Institute for
Child Health Research, Australia 
Abstract 
The homeoprotein TLX1, which is essential
to spleen organogenesis and oncogenic when
aberrantly expressed in immature T cells,
functions as a bifunctional transcriptional
regulator, being capable of activation or
repression depending on cell type and/or pro-
moter context. However, the detailed mecha-
nisms by which it regulates the transcription
of target genes such as ALDH1A1 remains to
be elucidated. We therefore functionally
assessed the ability of TLX1 to regulate
ALDH1A1 expression in two hematopoietic
cell lines, PER-117 T-leukemic cells and
human erythroleukemic (HEL) cells, by use of
luciferase reporter and mobility shift assays.
We showed that TLX1 physically interacts
with the general transcription factor TFIIB via
its homeodomain, and identified two activi-
ties in respect to TLX1-mediated regulation of
the CCAAT box-containing ALDH1A1 promot-
er. The first involved CCAAT-dependent tran-
scriptional repression via perturbation of
GATA factor-containing protein complexes
assembled at a non-canonical TATA (GATA)
box. A structurally intact homeodomain was
essential for repression by TLX1 although
direct DNA binding was not required. The
second activity, which involved CCAAT-inde-
pendent transcriptional activation did not
require an intact homeodomain, indicating
that the activation and repression functions
of TLX1 are distinct. These findings confirm
ALDH1A1 gene regulation by TLX1 and sup-
port an indirect model for TLX1 function, in
which protein-protein interactions, rather
than DNA binding at specific sites, are crucial
for its transcriptional activity.
Introduction 
TLX1 (HOX11), TLX2 and TLX3 belong to the
ancient NKL family of homeobox genes that
includes HEX, LBX1/2, MSX1/2, NKX3-2/BAPX1
and NKX2-5/CSX.
1 TLX1 encodes a transcrip-
tion factor that, although required during nor-
mal embryogenesis,
2,3 was actually discovered
as a consequence of its aberrant expression in
T-cell acute lymphoblastic leukemia (TALL).
4-7
Two distinct TLX1-expression categories have
been identified in T-ALL.
8,9 High level TLX1
expression (13%) is typically associated with
10q24 chromosomal abnormalities and confers
a favorable prognosis whereas TLX1-low 
T-ALLs (22%) have an intact 10q24 locus and
expression does not impact prognosis.
9
Aberrant expression of related TLX3 is addi-
tionally found in another 22% of T-ALLs follow-
ing 5q35 chromosomal rearrangements,
10
which highlights the significant role of TLX
family members in T-cell oncogenesis. 
Confirmation that the gene product of TLX1
is an oncoprotein has come from mouse mod-
els, which have shown that enforced expres-
sion of TLX1 impairs cell differentiation and
leads to malignancy.
11-15 Current models for the
mechanism by which TLX1 promotes leukemia
are based on its ability to act indirectly, either
by enhancing chromosome instability
16,17 or by
regulating gene expression through specific
protein-protein interactions with key cellular
regulatory molecules such as the protein ser-
ine/threonine phosphatases PP1 and PP2A,
and the transcriptional coactivator/acetyltrans-
ferase, CREB-binding protein (CBP).
18-20 Thus,
TLX1 may mediate its transforming function by
simultaneously inhibiting the phosphatase
activity of PP1/PP2A to promote cell cycle pro-
gression via upregulation of pathways such as
those downstream of E2F and MYC,
19 and
sequestering CBP at heterochromatin to
accomplish a differentiation block.
20
TLX1 has also long been suspected to act as
a sequence-specific transcription factor
21,22 that
preferentially binds to the core sequence
TAA
T/GTG in vitro.
22,23 However, with the excep-
tion of its associations with heterochromatic
satellite 2 DNA
24 and its own promoter,
25 no
direct target genes for TLX1 have been con-
vincingly identified. Individual genes suspect-
ed to be regulated by TLX1 have been described
in various settings, including spleen develop-
ment (Aldh1a1, Wt1),
26,27 erythroid differentia-
tion (ALDH1A1, c-Kit, Vegfc),
15,28 and T-cell
leukemia (ALDH1A1, FHL1, NR4A3).
26,29,30
Nevertheless, the regulatory role that TLX1
plays in such cases still remains to be deter-
mined. 
The best characterized TLX1 target gene,
ALDH1A1 (aldehyde dehydrogenase 1A1)
belongs to a subfamily (class 1A) of ALDH
genes whose main biological role is the con-
version of the aldehyde form of vitamin A (reti-
nal) to its biologically active form, retinoic
acid.
31 ALDH1A1 apparently has normal roles in
embryonic development,
32 and in the
renewal/differentiation of hematopoietic stem
cells (HSCs),
33 where it is known to be highly
expressed.
34 ALDH1A1 is further implicated in
regulating the polarity of HSC differentiation
by favoring the development of a myeloid
rather than a lymphoid cell fate.
30,35 In agree-
ment with this, ALDH1A1 expression can dis-
criminate between acute myeloid (AML) and
acute lymphoid leukemia,
36 and while we have
demonstrated aberrant ALDH1A1  expression
in T-ALL,
30 ALDH1A1 is reportedly down-regu-
lated in AML.
37 Thus, ALDH1A1, which is regu-
lated by TLX1 in its normal chromosomal con-
text
26,30 is of interest due to its associations
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with both normal development and leukemoge-
nesis. Here, we explored the molecular mecha-
nism(s) by which TLX1 regulates the ALDH1A1
gene and find that it occurs in a non-DNA bind-
ing fashion through protein-protein interac-
tions. We further show that TLX1 interacts
directly with the general factor TFIIB via its
homeodomain, indicating a role for TLX1 in
gene regulation via the basal transcriptional
machinery. 
Design and Methods 
Cell culture and expression plasmids 
The PER-117 and ALL-SIL T-cell lines, and
erythroleukemic cell line HEL, were cultured
as previously described.
30 The coding regions
of human TLX1 and TFIIB were amplified by
RT-PCR from ALL-SIL cDNA generated by
Thermoscript RT (Invitrogen, Carlsbad, CA,
USA) using PfuTurbo DNA Polymerase
(Stratagene, La Jolla, CA, USA) and primers
containing an Nhe I restriction site. The
resulting products were cloned into the Nhe I
site of the pCINeo mammalian expression vec-
tor (Promega, Madison, WI, USA) and
sequence verified. 
Luciferase reporter constructs 
The human ALDH1A1 proximal promoter
region was amplified by high-fidelity PCR from
genomic DNA as previously described.
29 For the
construction of the -978/+42 construct, a 1020
bp fragment of the ALDH1A1 promoter was
amplified using the forward primer 5’-
GCGAGCTCCACAATCAGAGCATCCAGAGTA-
3’and reverse primer 5’-GCGCTAGCCTCCTG-
GAACACAGGTGACTGGCT-3’ (introduced Sac
I/Nhe I restriction sites in italics). To create
the -303/+42, -201/+42, -146/+42 and -91/+42
constructs, various lengths of the ALDH1A1
promoter were amplified using the same
reverse primer together with the forward
primers 5’-GCGAGCTCAAAAAAATAATAACTG-
GCCTTAGTG-3’, 5’-GCGAGCTCCAGGTA-
CAAATTCGATGCTGGAGCACTGG-3’, 5’-
GCGAGCTCAAAGGCTTCCTGCCCTAGGTG-3’
and 5’-GCGAGCTCTGAGTTTGTTCATCCAATCG-
3’, respectively. The -50/+42 and +1/+42 con-
structs were generated directly by oligonu-
cleotide synthesis. All promoter fragments
were directionally cloned into the Sac I/Nhe I
sites of the luciferase reporter vector pGL3-
Basic (Promega, Madison, WI, USA). Insert
identities were confirmed by automated DNA
sequencing. The FHL1 -821 promoter construct
has been previously described.
38
Luciferase and β-galactosidase
reporter gene assays 
Plasmid DNAs (1 µg/µL), prepared using a
purification kit (Plasmid Maxi, QIAGEN,
Hilden, Germany), were transiently transfect-
ed as previously described.
39 In brief, PER-117
or HEL cells (1×10
7) were co-transfected by
electroporation (300V, 960 µF) with 15 µg of
luciferase reporter plasmid (or as negative
control, pGL3-Basic) and 5 µg of pSV-β-Gal
control plasmid. Cells were harvested 24 h
later followed by measurement of luciferase
and  β-galactosidase activities using the
Tropix Dual-Light luminescent reporter gene
assay system (Applied Biosystems, Foster City,
CA, USA). Transcriptional activity was defined
as the ratio of luciferase activity (in relative
light units; RLU) from pGL3-Basic derivatives
relative to β-galactosidase activity from pSV-
β-Gal, which reflected the efficiency of trans-
fection. All experiments were repeated a total
of three times on different days. 
For measuring the effect of TLX1 on
ALDH1A1 promoter activity, transfections
were similarly performed with the additional
inclusion of 15 µg of expression plasmid,
either pEF-BOS/TLX1, pEF-BOS/TLX1∆H3 or
pEF-BOS as control.
40 In this case, transcrip-
tional activity was defined as the log (base 2)
transformation of the ratio of luciferase activ-
ity (in relative light units; RLU) from pGL3-
Basic derivatives relative to β-galactosidase
activity from pSV-β-Gal. Statistical analysis
was performed in SPLUS 2000 using a mixed
effects model with day of experiment as a ran-
dom effect and luciferase reporter plasmid
and expression plasmid as fixed effects.
Interactions between contrasts comparing
pEF-BOS/TLX1 with pEF-BOS, and contrasts
comparing  ALDH1A1 constructs with pGL3-
Basic, were examined. This revealed the
extent to which the effect of adding TLX1 was
different for the various promoter constructs
compared to pGL3-Basic. 
Preparation of nuclear extracts 
Cells (1×10
7) were washed twice with 10
mL of cold PBS, resuspended in 400 µl Buffer
A (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM
EDTA, 0.1 mM EGTA) with protease inhibitors
(100 µg/mL aprotinin, 5 µg/ml leupeptin, 1
µg/ml pepstatin A, 0.5 mM PMSF) and incubat-
ed on ice for 30 min. 
NP-40 was added to a final concentration of
0.5% and the cells vortexed for 10 s. The nuclei
were pelleted by centrifugation at 6500 g for 1
min and resuspended in 100 µL Buffer C (20
mM HEPES, pH 7.9, 420 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 20% glycerol) with pro-
tease inhibitors. The nuclear suspension was
stirred vigorously on ice for 30 min. The sam-
ple was centrifuged at 13 000 g for 10 min, and
aliquots of the nuclear extract were frozen
immediately in liquid nitrogen and stored at
-80°C until required. The protein concentra-
tion of nuclear extracts was determined by the
Bradford assay (Bio-Rad Laboratories,
Hercules, CA, USA). 
Electrophoretic mobility shift assay
(EMSA) 
Double-stranded EMSA probes were pre-
pared from the following oligonucleotides:
ALDH CAT (5’-AGTTTGTTCATCCAATCGTATCC-
GAG-3’), ALDH CATMut (5’-AGTTTGTTCAT
gactgCGTATCCGAG-3’), ALDH GATAB (5’-GCC-
CGTGCAGATAAAAAAGGAACA-3’), ALDH
GATABMut (5’-GCCCGTGCActcagcAAAGGA
ACA-3’). Probes (20 pmol) were labeled by
incubation (37°C for 30 min) with T4 polynu-
cleotide kinase (15 U, Gibco BRL) and 40 µCi
[γ
32P]-ATP (3000 Ci/mmol) in a volume of 20
µL. The radiolabeled probes were purified
using Microspin G-50 columns (Amersham
Biosciences) and made double-stranded by
annealing with an equimolar amount of com-
plementary oligonucleotide in 1 x annealing
buffer (10 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1
mM EDTA). Probes were incubated in 1 x bind-
ing buffer (20 mM HEPES, pH 7.6, 50 mM KCl,
1 mM EDTA, 1 mM DTT, 5% glycerol) with 0.5
µg poly(dI-dC) (ICN, Costa Mesa, CA, USA)
and 6 µg of nuclear extract in a final volume of
15 µL. The samples were incubated at 4°C for
30 min and then analyzed by electrophoresis
on 4% native polyacrylamide gels in 0.5 x TBE
at 10 V/cm. For competition experiments, an
excess of unlabeled competitor oligonucleotide
was added to reaction mixtures. Additional
competitor oligonucleotides used were those
containing TLX1 (5’-TTCCATTCGATAATTC-
CATTCGA-3’) or GATA (5’-GAAACCTGT-
GATAAGTGTATGCAG-3’) binding sites.
Bandshifts were performed in the presence of
anti-TLX1 by adding 2 uL of polyclonal rabbit
antiserum raised against the C-terminus (sc-
880, Santa Cruz Biotechnology, Santa Cruz,
CA). Normal rabbit serum was used for the no
antibody control. Following electrophoresis,
the gels were transferred to 3MM paper
(Whatman, Maidstone, UK), dried and autora-
diographed at -80°C. 
Western blotting and immunopre-
cipitation of TLX1 complexes 
Western blotting was performed with 50 ug
of nuclear extract electrophoresed through a
12% SDS-PAGE gel and transferred to a Hybond
ECL membrane (AP Biotech, Little Chalfont,
UK). The membrane was blocked overnight in
TBS-Tween buffer (1 mM Tris, 7.5 mM NaCl,
0.05% v/v Tween-20) containing 3.5% (w/v)
gelatin and incubated with 1:1200 diluted rab-
bit anti-TLX1 antiserum (sc-880, Santa Cruz
Biotechnology) (1 h, RT). The membrane was
incubated with HRP-conjugated secondary
antibody (1 h, RT) prior to visualization of
bands by enhanced chemiluminescence (AP
Biotech). For immunoprecipitation, nuclear
extract from ALL-SIL cells (5×10
6) was pre-
cleared with the addition of protein A/G
agarose (Santa Cruz Biotechnology) for 15
min at 4°C. Pre-cleared extracts were incubat-
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ed with 5 µg of affinity-purified rabbit anti-
TLX1 polyclonal antibody (sc-880; Santa Cruz
Biotechnology), or no antibody (as control), for
4 h at 4°C with constant gentle rocking.
Immune complexes were bound to protein A/G
agarose beads, centrifuged and washed with
1.2 mL of cold IP wash buffer (100 mM Tris-HCl
pH 7.4, 1% NP40 and 1% deoxycholic acid) con-
taining 500 mM LiCl (once) and 1.2 mL of IP
wash buffer (four times). 
MALDI-TOF mass spectrometric
analyses 
Immunoprecipitated proteins were resolved
by SDS-PAGE and visualized by silver stain-
ing.
41 Bands were excised directly from gels
into 96-well microtiter plates (Titertek,
Huntsville, AL, USA), destained,
42 and in-gel
trypsin digestions performed according to
Shevchenko  et al.
41 Peptides were extracted
with 10 mg/mL α-cyano-4-hydroxycinnamic
acid in 50% acetonitrile containing 0.1% triflu-
oroacetic acid, and aliquots of 0.5 uL applied
directly onto a target plate and allowed to air
dry. Tryptic peptide masses were then obtained
using a Voyager-DE STR MALDI-TOF mass
spectrometer (Applied Biosystems, Foster City,
CA, USA). Known trypsin autocleavage peptide
masses (842.51, 1045.56 and 2211.1 Da) were
used for internal calibration of each spectrum.
The peptide masses were used to search the
Swiss-Prot and NCBI nr protein databases
using the MS-FIT database tool. A protein was
considered to be identified if a minimum of
five measured peptide masses matched calcu-
lated tryptic peptide masses and if the peptides
identified by these matches provided at least
20% sequence coverage of the identified pro-
tein. 
GST-pulldown assay 
TLX1 and TFIIB cDNAs in pCIneo were tran-
scribed in vitro with T7 RNA polymerase. The
products were labeled with [
35S]-methionine
(Amersham Biosciences) using the TNT cou-
pled transcription-translation system (Prome-
ga). GST-TLX1 fusion proteins were expressed
from pGEX-6P-1 as described previously.
43 The
GST-pulldown assay was performed by incubat-
ing 15 µg of GST, GST-TLX1 or GST-TLX1∆H3
immobilized on glutathione sepharose beads
(20 µL) with 5 µl of proteins translated in vitro
and labeled with [35S]-methionine in 500 µL
of binding buffer (50 mM Tris-HCl, pH 7.5, 150
mM NaCl, 0.5 mM EDTA, 0.5% NP-40, 1 mM
DTT, 0.5 mM PMSF, 0.05% BSA) for 18-20 h at
4°C with continuous rotation. Bound proteins
were washed three times with 500 µL of cold
binding buffer and eluted in SDS sample
buffer. The eluted proteins were resolved on
12% SDS-PAGE gels and visualized by autora-
diography.
Results 
Functional analysis of the human
ALDH1A1 promoter 
Ectopic expression of TLX1 was previously
shown to modulate endogenous ALDH1A1
expression.
26,30,38 To pursue the molecular
mechanism(s) underlying this regulatory
effect, we cloned 1020 bp of the human
ALDH1A1 5’-flanking region into the pGL3-
Basic luciferase reporter vector. This sequence
comprised nucleotides -978 to +42 relative to
the transcriptional start site (Figure 1). Among
the conserved promoter elements identified
were a TATA-like sequence (GATA box) at -33
and a single CCAAT box at -74, which has pre-
viously been shown to be functionally impor-
tant for ALDH1A1 expression.
44 Transient
transfection of a series of deletion constructs
(-978/+42, -303/+42, -201/+42, -146/+42, -91/
+42, -50/+42 and +1/+42; Figure 1) into PER-
117 and HEL cells (which both lack TLX1
expression) showed that the ALDH1A1promot-
er was functional in both cell lines and that the
sequences between -50 and -91 and between -
50 and -146 were required for maximal promot-
er activity in PER-117 and HEL cells, respec-
tively (Figure 2A). Consistent with previous
results in Hep3B liver cells,
44 deletion of the
CCAAT box at -74 caused a dramatic reduction
in promoter activity, suggesting that it is a key
element for ALDH1A1 expression in multiple
cell types. 
Regulation of the ALDH1A1 pro-
moter by TLX1 
To determine the effect of TLX1 on the tran-
scriptional activity of the ALDH1A1 promoter,
transactivation assays were carried out in
PER-117 and HEL cells co-transfected with an
expression plasmid containing TLX1 or empty
vector (pEF-BOS) as a negative control. The
results were expressed as a ratio of the nor-
malized transcriptional activity of each of the
two promoter constructs with and without
TLX1 (Figure 2B). Western blot analysis con-
firmed that TLX1 protein was expressed in the
transfected cells (Figure 2C). Consistent with
our previous findings,
15,29,38 the effect of TLX1
Article
Figure 1. Nucleotide sequence alignment of the human and mouse ALDH1A1 promoters.
Conserved nucleotides are marked with an asterisk. Numbers at right indicate nucleotide
positions of the human sequence relative to the transcriptional start site (bent arrow).
Potential regulatory elements, including a conserved TLX1 site at -257, are boxed and
labeled. Solid triangles with numbers demarcate the 5’ ends of the promoter deletion con-
structs used in the luciferase reporter assays. The two regions used for gel shift analysis are
underlined at -85 to -60 and -42 to -19. BRE, TFIIB recognition element. [Hematology Reviews 2009; 1:e13] [page 73]
on ALDH1A1 was reversed in the transcription-
al assay as compared to regulation of the
endogenous gene. In PER-117 cells, TLX1
repressed ALDH1A1 promoter activity (Figure
2B), and this required the sequence between 
-50 and -91, which contains the CCAAT box.
Deletion of the CCAAT box (-91∆CAT) com-
pletely abolished TLX1-mediated repression
(Figure 2B), suggesting that downregulation
may possibly occur via this site. Interestingly,
the shortest constructs (-50/+42 and +1/+42)
were mildly stimulated by TLX1 in both PER-
117 and HEL cells, (Figure 2B) indicating the
presence of a separate, positive-acting TLX1-
response sequence localized to the region
between +1 and +42. No effect by TLX1 was
observed on the region between -201 and -303,
which contains a conserved TLX1 in vitro bind-
ing site at -257 (Figure 1), suggesting that
TLX1 binds to a distinct recognition sequence
in the ALDH1A1 promoter in vivo, or alterna-
tively, that it acts via a non-DNA binding mech-
anism. In either case, these data indicate that
TLX1 operates via at least two mechanisms in
respect to the ALDH1A1 promoter; a general
transactivating activity via an element located
between +1 and +42 and a strong, cell line-
specific repressive activity via an element
located between -91 and -50. 
The homeodomain is required for
TLX1-mediated repression 
To assess whether the homeodomain of
TLX1 is required for the transcriptional activi-
ties of TLX1, a mutant TLX1 expression vector
(TLX1∆H3) was employed, which lacks the
DNA recognition helix (helix 3) of the home-
odomain. Whereas, TLX1 repressed the activity
of the basal ALDH1A1 promoter (-91/+42) 4-
fold in PER-117 cells, TLX1∆H3 not only lacked
the ability to negatively regulate ALDH1A1, but
switched to become an activator, stimulating
transcription by approximately 5-fold (Figure
3). A similar result was obtained when the pro-
moter of another target gene, FHL1,
38 was used
(Figure 3). By contrast, the positive regulation
of the -91/+42 construct observed in HEL cells
was comparable when either TLX1 or TLX1∆H3
was used (5.5-and 8-fold induction, respective-
ly). Thus, the homeodomain is crucial for
TLX1-mediated repression but is not required
for TLX1-mediated activation, indicating that
these two activities are distinct. 
TLX1 does not affect formation of
transcriptional complexes at the -74
CCAAT site 
We opted to focus on the mechanism by
which TLX1 mediates CCAAT-dependent
repression. Mobility shift assays were there-
fore performed to identify whether TLX1
directly binds to the CCAAT box or interferes
with the binding of other factors at this site.
Nuclear extracts derived from PER-117 or HEL
cells, either expressing empty pEF-BOS (as
control) or pEF-BOS/TLX1, were incubated
with a radiolabeled probe (ALDH CAT) span-
ning the CCAAT motif (-85 to -60; Figure 1). As
shown in Figure 4A, incubation of nuclear
extract from PER-117 or HEL cells with ALDH
CAT resulted in the appearance of at least two
specific DNA-protein complexes, together with
a third non-specific complex (C2). The
strongest, complex C1, appeared to be common
to the two cell types, while additional complex-
es P and H were unique to PER-117 and HEL
cells, respectively. These complexes were
inhibited by the addition of a 35-fold molar
excess of unlabeled self-competitor (ALDH
CAT) but not by a 35-fold molar excess of
CCAAT mutant competitor (ALDH CATMut;
CCAAT to GACTG). Contrary to expectation, in
both PER-117 and HEL cells the mobility shift
pattern was identical regardless of TLX1
Article
Figure 2. Activity of the human
ALDH1A1 promoter and its differential
regulation by TLX1. (A) ALDH1A1 pro-
moter activity in the hematopoietic cell
lines PER-117 and HEL. Luciferase activ-
ity expressed as fold-change over the pro-
moter-less pGL3-Basic vector after nor-
malizing the luciferase signals to a β-
galactosidase transfection control. The
indicated  ALDH1A1 promoter deletion
constructs were transiently transfected
into PER-117 cells (black bars) and HEL
cells (gray bars). Deletion of the CCAAT
box (-91∆CAT construct) abrogates pro-
moter activity. The values represent the
average of duplicate data points from
three independent experiments. (B) The
ALDH1A1 promoter is differentially reg-
ulated by TLX1 in PER-117 and HEL
cells. The indicated ALDH1A1 luciferase
reporter constructs were co-electroporat-
ed with a TLX1 expression plasmid and
β-galactosidase expression plasmid into
the cell lines PER-117 (black bars) and
HEL cells (gray bars). Transactivation/
repression is shown as the fold-change
(on a log2 scale) compared to background
levels obtained when an empty expression
vector (no TLX1) was co-electroporated.
Asterisks denote fold changes that were
statistically different to zero (p<0.05).
The -91∆CAT construct harbors a dele-
tion of the CCAAT box. (C) Western blot
confirming TLX1 protein expression in
the transiently transfected PER-117 and
HEL cells. U, untransfected controls; T,
TLX1 transfected. The faint band
observed in the controls is non-specific. 
Figure 3. TLX1 requires an intact home-
odomain for transcriptional repression
but not activation  in vitro. Luciferase
activity of the ALDH1A1 -91/+42 and
FHL1 -821/+181 promoter constructs
cotransfected into the indicated cell lines
with either an empty expression vector as
negative control (striped bars), TLX1
(black bars) or TLX1∆H3, a mutant lack-
ing helix 3 of the homeodomain (gray
bars). The values represent the average of
duplicate data points from three inde-
pendent experiments. 
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expression status (or addition of TLX1 anti-
body; data not shown), suggesting that TLX1
does not affect the formation of DNA-protein
complexes at the CCAAT box. 
TLX1 alters DNA-protein complex
formation at the -33 GATA box 
TLX1 may directly or indirectly inhibit
CCAAT-dependent transcription via the basal
apparatus. The ALDH1A1 promoter lacks a
canonical TATA box but does possess a related
GATA box (GATAAA) utilized by a number of
genes whose transcriptional initiation involves
interplay between TFIID and GATA factors.
45-48
EMSAs were thus performed to identify
whether TLX1 directly binds to the GATA box or
interferes with the binding of other factors at
this site. Nuclear extracts derived from PER-
117 or HEL cells, either expressing empty pEF-
BOS (as control) or pEF-BOS/TLX1, were incu-
bated with a radiolabeled probe (ALDH GATAB)
spanning the GATA box (-42 to -19; Figure 1).
As shown in Figure 4B, incubation of nuclear
extract from PER-117 cells lacking TLX1
expression with ALDH GATAB resulted in the
appearance of four specific DNA-protein com-
plexes, C1, C2, P1 and P2. HEL nuclear extracts
only produced three specific complexes (C1,
C2 and H), the strongest of which (C2)
appeared to migrate similarly in both cell
types. These complexes were inhibited by the
addition of a 35-fold molar excess of unlabeled
self-competitor (ALDH GATAB) but not by a 35-
fold molar excess of GATA box mutant competi-
tor (ALDH GATABMut; GATAAA to CTCAGC).
Strikingly, in PER-117 but not HEL cells,
expression of TLX1 resulted in a significant
alteration in complex formation. Of the four
specific PER-117 complexes, the formation of
two (C1 and P1) was completely inhibited by
TLX1, while the intensity of the remaining two
(C2 and P2) was enhanced. Thus, TLX1-medi-
ated regulation of ALDH1A1 in T cells, but not
erythroid cells, is associated with an alteration
of transcription factor binding at the GATA box. 
Complex formation at the GATA box in both
PER-117 and HEL cells was also strongly inhib-
ited when a 35-fold molar excess of an unla-
beled consensus GATA oligonucleotide (GATA;
containing WGATAR with different flanking
sequences to ALDH GATAB) was used (Figure
5A). This indicated that GATA factors are pres-
ent in all complexes formed in this assay.
However, TLX1 does not appear to bind DNA at
this site, since a 35-fold molar excess of an
unlabeled consensus satellite 2 oligonu-
cleotide (TLX1), capable of being bound by
TLX1,
24 could not compete for complex forma-
tion (Figure 5A). In agreement with this con-
clusion, no supershift or inhibition of complex
formation was observed following addition of
TLX1 antibody (Figure 5B). Notably, however,
PER-117 complex C1, which is abolished by
TLX1, re-formed in the presence of TLX1 anti-
body, indicating that TLX1 directly contributes
to the disruption of this low mobility complex. 
TLX1 interacts with TFIIB 
To help understand the transcriptional regu-
latory function of TLX1, we searched for bind-
ing partners using an immunoprecipitation
strategy in leukemic T cells (ALL-SIL) that
Article
Figure 4. Effect of TLX1 on ALDH1A1 promoter DNA-binding complexes. (A) TLX1 does not affect DNA-protein complex formation
at the -74 CCAAT box. EMSA using a 
32P-labeled double-stranded oligonucleotide containing the CCAAT site at -74 of the human
ALDH1A1 promoter (ALDH CAT). The assay was performed with nuclear extracts prepared from PER-117 (left lanes) or HEL cells
(right lanes) with and without overexpression of TLX1. The migration of the free probe is indicated along with the positions of specif-
ic DNA-protein complexes (C1 and P in PER¬117 cells; C1 and H in HEL cells). Overbars denote the addition of a 35-fold molar excess
of unlabeled double-stranded self (ALDH CAT) or mutant (ALDH CATMut) probe as competitor. (B) TLX1 alters DNA-protein com-
plex formation at the -33 GATA box. EMSA performed as above using a labeled oligonucleotide containing the GATAAA site at -33 of
the human ALDH1A1 promoter (ALDH GATAB). The migration of the free probe is indicated along with the positions of specific DNA-
protein complexes (C1, C2, P1 and P2 in PER-117 cells; C1, C2 and H in HEL cells). Overbars denote the addition of a 35-fold molar
excess of unlabeled double-stranded self (ALDH GATAB) or mutant (ALDH GATABMut) probe as competitor. Asterisks denote com-
plexes altered by TLX1. 
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aberrantly express TLX1 as a consequence of a
10q24 chromosomal translocation. A TLX1
antibody was employed to isolate naturally
occurring nuclear protein complexes, which
were separated by SDS-PAGE and silver
stained (Figure 6A). Excised gel slices repre-
senting discrete molecular mass intervals
were digested with trypsin and analyzed by
MALDI-TOF mass spectrometry in order to
determine the identity of the protein bands.
Table 1 summarizes the eight proteins detect-
ed. Among these were the centromeric pro-
teins CENP-E and CENP-F, an intriguing find-
ing given that TLX1 has previously been local-
ized to centromeric regions.
24 Of particular
interest was the detection of the general tran-
scription factor TFIIB, which was identified by
the presence of 15 peptides with sequence cov-
erage of 49% (Table 1). To confirm that TLX1
could physically interact with TFIIB in a specif-
ic manner, we performed a GST pulldown assay
(Figure 6B). Glutathione-Sepharose beads
containing GST-TLX1, GST-TLX1∆H3, or GST
alone were incubated with in vitro translated
35S-labeled TFIIB or TLX1 protein. The latter
was included as a positive control since TLX1
has previously been shown to homodimerize.
24
Following extensive washing, retention of
TFIIB was observed with GST-TLX1 but not
with control GST beads (Figure 6B), demon-
strating that TLX1 has the capacity to interact
with TFIIB. Interestingly, retention of TFIIB,
but not TLX1 control, was greatly diminished
when GST-TLX1∆H3 beads were used, indicat-
ing that helix 3 of the TLX1 homeodomain con-
tributes strongly to the TFIIB interaction. 
Discussion 
TLX1 has previously been characterized as a
DNA-binding factor that preferentially associ-
ates with the core sequence TAA
T/GTG in vitro
22,23 and the similar sequence T
A/GATTC present
in satellite 2 DNA.
24 In addition, TLX1 can
switch, in a cell type- and promoter context-
dependent manner, between roles as activator
and repressor,
26,30,38 however the mechanism(s)
responsible for these divergent roles is poorly
understood. In this study, we further investi-
gated the function of TLX1 by analyzing its
ability to transcriptionally regulate ALDH1A1,a
gene previously identified as being TLX1-
dependent in developing mouse spleen as well
as in several cell lines (PER-117, HEL, NIH-
3T3),
26,30,49 and which contains a predicted TLX1
binding site, conserved between human and
mouse, at -257 upstream of the transcriptional
start site. In the first instance, our data con-
firmed ALDH1A1as a regulatory target of TLX1,
with the polarity of effect observed in terms of
activation/repression being heavily dependent
upon cell type. In PER-117 T cells, transient
luciferase reporter assays with nested dele-
tions of the ALDH1A1 promoter revealed that
TLX1-mediated repression occurred in a
CCAAT box-dependent manner involving an
element located between -91 and -50. By con-
trast, TLX1 stimulated transcription in a
CCAAT-independent manner from a proximal
location (-91/+42) in human erythroleukemic
Article
Figure 5. Perturbation of GATA-containing complexes by TLX1. (A) GATA factor(s) but not TLX1 binds to the ALDH1A1 promoter
GATA box. EMSA using a 32P-labeled double-stranded oligonucleotide containing the GATAAA site at -33 of the human ALDH1A1
promoter (ALDH GATAB). The assay was performed with nuclear extracts prepared from PER-117 (left panel) or HEL cells (right
panel) with and without overexpression of TLX1. The migration of the free probe is indicated along with the positions of specific DNA-
protein complexes (C1, C2, P1 and P2 in PER-117 cells; C1, C2 and H in HEL cells). Overbars denote the addition of a 35-fold molar
excess of unlabeled double-stranded self (ALDH GATAB), satellite 2 DNA (TLX1) or GATA consensus (GATA) probe as competitor.
Asterisks denote complexes altered by TLX1. (B) TLX1 directly disrupts the low mobility ALDH1A1 promoter GATA box complex C1.
EMSA performed as above using the -33 GATAAA site oligonucleotide (ALDH GATAB) in the absence (-) or presence (+) of TLX1 anti-
body. The migration of the free probe is indicated along with the positions of specific DNA-protein complexes (C1, C2, P1 and P2 in
PER-117 cells; C1, C2 and H in HEL cells). Complex C1 reappears in PER-117 cells expressing TLX1 in the presence of anti-TLX1 anti-
body (asterisk). 
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(HEL) cells. Transactivation, which was also
observed in the T-cell background when a min-
imal promoter sequence was used (-50/+42),
was abolished in HEL cells with the addition of
extra DNA sequence (-146/-92) suggesting
that a specific factor bound to this region is
capable of abrogating the stimulatory potential
of TLX1. Thus, TLX1 possessed two activities in
respect to the ALDH1A1 promoter, namely
CCAAT-dependent repression, which was cell
type-specific and cryptic CCAAT¬independent
activation, which was unmasked by deleting
upstream regulatory sequences. Neither of
these activities involved the TLX1 recognition
site at -257, which initially suggested that
TLX1 either bound a distinct sequence in vivo,
as is the case with the regulation of its own
promoter,
25 or that it acted via a non-DNA bind-
ing mechanism. 
Remarkably, the effect of TLX1 on ALDH1A1
promoter activity in the transient reporter
assays was inversely related to its previously
observed effect on endogenous ALDH1A1 lev-
els in PER-117 and HEL cells.
30 This phenome-
non has been observed previously in respect to
other putative gene targets of TLX1, namely
NR4A3, KIT and FHL1.
15,29,38 Although puzzling,
the finding that a homeoprotein can act as a
repressor or activator of transcription depend-
ing on promoter context is a common one. In
many cases the activity that predominates has
been found to be highly dependent on the
nature of the cis-regulatory DNA sequence
since this can, in turn, affect the interaction of
homeoproteins with co-regulatory molecules
such as TALE (three amino acid loop exten-
sion) homeoproteins, CBP (CREB-binding pro-
tein) or Groucho.
50-54
CCAAT-dependent repression by TLX1 was
found to require the DNA recognition helix
(helix 3) of the homeodomain. Intriguingly,
the TLX1∆H3 mutant lacking this helix was
not only incapable of repressing ALDH1A1
transcription in PER-117 cells but switched to
become an activator of transcription. This indi-
cated that the repression/activation activities
of TLX1 are separable with a structurally intact
homeodomain being absolutely required for
transcriptional repression, but not activation.
Given these findings, a reasonable assumption
was that TLX1 would repress ALDH1A1 tran-
scription by directly binding promoter DNA at
or near the CCAAT box. This crucial element is
likely generally required for ALDH1A1 expres-
sion, since it was also identified as the major
positive element in the Hep3B cell line and in
Hepa-1 mouse hepatoma cells where it was
bound by NF-Y and CCAAT/enhancer binding
protein β (C/EBPβ), respectively.
44,55 Moreover,
the CCAAT box is capable of being bound by
the CCAAT binding transcription factor
(CTF1/NFIC) with which TLX1 is known to
interact in a functional manner.
56 However,
EMSA assays using PER-117 (or HEL) nuclear
extracts revealed that TLX1 did not directly
bind the CCAAT box, nor did it affect protein
Article
Table 1. Proteins identified by immunoprecipitation and peptide mass fingerprinting.
Identified protein Matched Mass UniProtKB/Swiss-Prot
peptide cover (kDa) accession number
(%)
General transcription factor IIB (TFIIB) 49 34.83 Q00403
Centromere protein F (CENPF) 39 367.76 P49454
Centromere protein E (CENPE) 35 316.42 Q02224
RAD50 homolog (RAD50) 31 153.89 Q92878
Retinoblastoma binding protein 9 (RBBP9) 28 21.00 O75884
NK homeobox 6-1 (NKX6-1) 28 37.85 P78426
Lymphoblastic leukemia 1 (LYL1) 23 28.63 P12980
Zinc finger protein 20 (ZNF20) 20 61.57 P17024
Figure 6. TLX1 interacts with TFIIB.
(A) Isolation of TLX1-associated pro-
teins. Nuclear extracts from ALL-SIL
leukemic T cells were immunoprecip-
itated using TLX1-specific antibody
(Ab), or no antibody (No Ab) as neg-
ative control. Coprecipitated proteins
were resolved by SDS-PAGE and sil-
ver stained. (B) GST pulldown assay.
GST, GST-TLX1 and GST-TLX1∆H3
immobilized on glutathione-
Sepharose beads were incubated with
in vitro-translated, 
35S-labeled TLX1
as positive control, and TFIIB. Bound
proteins were washed, eluted, resolved
by 12% SDS-PAGE and detected by
autoradiography: 50% of the labeled
input proteins TLX1 and TFIIB are
shown on the left. 
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complex formation at this site. We therefore
hypothesized that TLX1 may abrogate CCAAT-
dependent transcription of ALDH1A1 by acting
through the basal transcriptional apparatus.
Supporting this notion, a previous study
demonstrated that TLX1 is capable of repress-
ing transcription via the RNA polymerase II
holoenzyme in a manner that is DNA-inde-
pendent, yet requires helix 3 of the home-
odomain.
49 Indeed, we found that TLX1 altered
the formation of GATA-containing protein com-
plexes at the non-canonical TATA (GATA) box
located at -33 on the ALDH1A1 promoter and
that this occurred specifically in PER-117 cells
where repression by TLX1 was observed. The
GATA box is a dual regulatory site capable of
binding both GATA factors and members of the
basal transcriptional machinery, which is over-
represented among erythroid-specific gene
promoters. Studies to date have indicated that
the GATA box is a specialized/weakened TATA
box
57 whose activity depends on interplay
between binding of GATA factors and general
transcription factors such as TFIID.
45-48 Based
on our data, we therefore postulate that TLX1
can operate as a transcriptional repressor by
altering the balance between specific factors
binding at the GATA box without actually bind-
ing DNA itself. This, at least in part, may
involve direct protein contacts by TLX1 since
inclusion of anti-TLX1 antibody into EMSA
binding reactions reduced TLX1-associated
inhibition of one of the GATA box complexes
identified. Intriguingly, the related HEX pro-
tein has been reported to interact with GATA2
to inhibit its binding to the flk-1/KDR gene,
58
suggesting that direct antagonism of GATA fac-
tors may be a feature of NKL homeoprotein
function more generally.
We further showed that TLX1 specifically
interacts with TFIIB, a member of the general
transcriptional machinery. TFIIB, which can
bind promoter DNA in a sequence-specific
manner at a TFIIB recognition element (BRE),
plays a central role in pre-initiation complex
(PIC) assembly, providing a bridge between
promoter-bound TFIID and RNA polymerase II.
This points to a mechanism to account for how
TLX1 can inhibit basal transcription in a non-
DNA binding manner, both in this study and
that of Owens et al.
49 Specifically, TLX1 may
directly affect repression of the ALDH1A1 pro-
moter, which contains a BRE adjacent to the
GATA box, by inhibiting the rate/extent of PIC
formation via contacts with TFIIB. Notably, the
TLX1-TFIIB interaction was reduced in the
absence of homeodomain helix 3. Thus our
results provide one potential mechanism to
explain the switch in activity from repression
to activation observed with the TLX1∆H3
mutant. 
Significantly, it has been recently reported
that TLX1, like many other homeoproteins,
52
can form a mutually inhibitory complex with
the co-activator/histone acetyltransferase mol-
ecule CBP.
20 This interaction leads to seques-
tration of CBP at repressive chromatin
domains, which is consistent with our previ-
ous finding that TLX1 can localize to hete-
rochromatin via binding at satellite 2 DNA.
24
The TLX1-CBP interaction was also shown to
require helix 3 of the TLX1 homeodomain,
thereby suggesting an alternative, although
not mutually exclusive, explanation for TLX1-
mediated repression and its reversal in the
TLX1∆H3 mutant. Riz et al.
20 further showed a
correlation between the presence of TLX1 and
a lack of CBP-associated acetylation of GATA1.
As is the case for GATA2 and GATA3,
59,60 the
DNA binding and transcriptional activity of
GATA1 is heavily dependent on its acetylation
status.
61 Taken together, we suggest a model in
which interactions between TLX1 and both
TFIIB and CBP lead to the transcriptional
repression observed in our transient luciferase
assays. Whereas contacts with TFIIB may
inhibit the formation of a functional PIC, bind-
ing to CBP may prevent it functioning as a co-
activator and acting to acetylate GATA factors.
This would explain the substantially altered
formation of GATA-containing protein com-
plexes observed at the ALDH1A1 promoter
GATA box, despite the lack of DNA binding by
TLX1. It is conceivable that a general ability of
TLX1 to indirectly regulate target genes by
altering GATA factor activity, whether via CBP
or an alternative mechanism, may be conse-
quential for its role as an oncoprotein. This is
particularly in view of evidence linking both a
blockage in T-cell development and leukemo-
genesis to incapacitated GATA function.
62,63
Interestingly, a non-DNA binding mode of
action for TLX1 that involves activity regula-
tion of other transcription factors is reminis-
cent of another important T-ALL oncoprotein,
SCL/TAL1, which induces leukemia by recruit-
ing the co-repressor/histone deacetylase
mSin3A to inhibit the transcriptional activity
of E47/HEB.
64
There is little evidence to date showing that
TLX1 can bind directly to natural DNA
sequences to regulate target gene expression.
Instead, TLX1 has been shown to operate indi-
rectly by interacting with other proteins, most
notably the phosphatases PP1 and PP2A to reg-
ulate gene cascades in various pathways such
as RB/E2F and p107/MYC.
18,19 Consistent with
this paradigm, our data confirm that TLX1 is
capable of regulating ALDH1A1 expression in a
non-DNA binding manner by affecting tran-
scriptional complexes at the proximal
ALDH1A1 promoter, although clearly, addition-
al cis-regulatory elements (that may influence
TLX1 protein interactions) are required to
recapitulate the effect of TLX1 on endogenous
ALDH1A1 gene expression. We showed that
TLX1, like other homeodomain transcription
factors including tinman/Nkx2-5, abdominal-A,
Nkx6.1 and Vnd/Nkx2-2
51,53,54,65 is capable of act-
ing as a bi-functional transcriptional regulator,
whose activation and repression activities
operate in a cell-type specific manner and via
two distinct mechanisms. The first involves
the ability of TLX1 to repress transcription,
possibly by perturbing interactions between
CCAAT box-binding transcriptional activators
and proteins (GATA factors/basal transcription-
al machinery) assembled at a non-canonical
TATA (GATA) box. This activity does not appear
to involve direct DNA binding, although a
structurally intact homeodomain is required,
presumably in order for TLX1 to interact with
TFIIB and/or CBP. Chromatin immunoprecipi-
tation assays to identify the specific transcrip-
tion factor(s) bound at this composite CCAAT-
box/TLX1 responsive element and at the GATA
box before and after TLX1 expression are
required to substantiate this hypothesis. The
second activity involves the ability of TLX1 to
stimulate transcription through as yet uniden-
tified regulatory elements in the proximal
ALDH1A1 promoter and does not require an
intact homeodomain. Our understanding of
the role of TLX1 in normal development and in
T-cell leukemogenesis is crucially dependent
on deciphering the mechanisms by which
TLX1 is capable of regulating gene expression.
Future work to characterize TLX1 target genes
and to fully define the protein participants
involved in TLX1-mediated gene regulation
will represent important steps towards this
goal. 
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